Company Quick10K Filing
Quick10K
Dariohealth
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.62 38 $24
10-Q 2019-06-30 Quarter: 2019-06-30
10-Q 2019-03-31 Quarter: 2019-03-31
10-K 2018-12-31 Annual: 2018-12-31
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
10-Q 2017-06-30 Quarter: 2017-06-30
10-Q 2017-03-31 Quarter: 2017-03-31
10-K 2016-12-31 Annual: 2016-12-31
10-Q 2016-09-30 Quarter: 2016-09-30
10-Q 2016-06-30 Quarter: 2016-06-30
10-Q 2016-03-31 Quarter: 2016-03-31
10-K 2015-12-31 Annual: 2015-12-31
10-Q 2015-09-30 Quarter: 2015-09-30
10-Q 2015-06-30 Quarter: 2015-06-30
10-Q 2015-03-31 Quarter: 2015-03-31
10-K 2014-12-31 Annual: 2014-12-31
10-Q 2014-09-30 Quarter: 2014-09-30
10-Q 2014-06-30 Quarter: 2014-06-30
10-Q 2014-03-31 Quarter: 2014-03-31
10-K 2013-12-31 Annual: 2013-12-31
8-K 2019-07-08 Shareholder Rights, Exhibits
8-K 2019-07-02 Other Events
8-K 2019-05-22 Enter Agreement, Exhibits
8-K 2019-05-21 Other Events, Exhibits
8-K 2018-12-28
8-K 2018-12-13 Enter Agreement, Sale of Shares, Exhibits
8-K 2018-11-29 Officers, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-10-15 Officers
8-K 2018-09-13 Amend Bylaw
8-K 2018-09-07 Enter Agreement, Sale of Shares
8-K 2018-08-30 Officers
8-K 2018-06-29 Officers
8-K 2018-05-18 Officers, Shareholder Vote, Exhibits
8-K 2018-04-01 Officers, Shareholder Vote
8-K 2018-02-28 Enter Agreement, Sale of Shares, Amend Bylaw, Exhibits
BAX Baxter 43,757
PODD Insulet 9,038
ABMD Abiomed 8,576
INSP Inspire Medical Systems 1,579
ATRC Atricure 1,049
OFIX Orthofix Medical 979
SIBN SI-BONE 477
TRXC Transenterix 200
ELGX Endologix 89
ISR Isoray 24
DRIO 2019-06-30
Note 1: - General
Note 2: - Significant Accounting Policies
Note 3: - Unaudited Interim Financial Statements
Note 4: - Inventories
Note 5: - Revenue
Note 6: - Commitments and Contingent Liabilities
Note 7: - Leases
Note 8: - Stockholders' Equity
Note 9: - Financial Expenses, Net
Note 10: - Subsequent Events
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Item 4. Controls and Procedures.
Part Ii- Other Information
Item 6. Exhibits.
EX-31.1 tv526523_ex31-1.htm
EX-31.2 tv526523_ex31-2.htm
EX-32.1 tv526523_ex32-1.htm
EX-32.2 tv526523_ex32-2.htm

Dariohealth Earnings 2019-06-30

DRIO 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 tv526523_10q.htm FORM 10-Q

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2019

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                    

 

Commission File No. 001-37704

 

DarioHealth Corp.
(Exact name of registrant as specified in its charter)

 

Delaware 45-2973162
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)

 

8 HaTokhen Street  
Caesarea Industrial Park, Israel 3088900
(Address of Principal Executive Offices) (Zip Code)

 

+972-4-7704055
(Registrant’s telephone number, including area code)

 

n/a
(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x   No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x  No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

¨ Large accelerated filer ¨ Accelerated filer
x Non-accelerated filer x Smaller reporting company
    ¨ Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨   No x

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class   Trading Symbol(s)   Name of exchange on which
registered
Common Stock, par value $0.0001 per share   DRIO   The Nasdaq Capital Market LLC
Warrants to purchase Common Stock   DRIOW   The Nasdaq Capital Market LLC

 

As of August 12, 2019, the registrant had 43,601,280 shares of common stock outstanding.

 

When used in this quarterly report, the terms “DarioHealth,” “the Company,” “we,” “our,” and “us” refer to DarioHealth Corp., a Delaware corporation and our subsidiary LabStyle Innovation Ltd., an Israeli company. “Dario” is registered as a trademark in the United States, Israel, China, Canada, Hong Kong, South Africa, Japan, Costa Rica and Panama. “DarioHealth” is registered as a trademark in the United States and Israel.

 

 

 

 

 

  

DarioHealth Corp.

 

Quarterly Report on Form 10-Q

 

TABLE OF CONTENTS

 

  Page 
   
Cautionary Note Regarding Forward-Looking Statements 3
   
PART 1-FINANCIAL INFORMATION  
     
Item 1. Consolidated Financial Statements (unaudited) F-1
     
  Consolidated Balance Sheets F-2
     
  Consolidated Statements of Comprehensive Loss F-4
     
  Statements of Changes in Stockholders’ Equity F-5
     
  Consolidated Statements of Cash Flows F-7
     
  Notes to Consolidated Financial Statements F-8
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 4
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 9
     
Item 4. Control and Procedures 10
   
PART II-OTHER INFORMATION  
     
Item 6. Exhibits 11
   
SIGNATURES 12
   
 2 

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

 

  our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise;
     
  our launch and market penetration plans;
     
  our ability to manufacture, market and generate sales of our Dario Smart Diabetes Management Solution;
     
  our ability to commercialize DarioEngage;
     
  our ability to develop, launch and commercialize Dario Intelligence;
     
  our ability to maintain our relationships with key partners;
     
  our ability to complete required clinical trials of our product and obtain clearance or approval from the United States Food and Drug Administration, or FDA, or other regulatory agencies in different jurisdictions;
     
  our ability to maintain or protect the validity of our U.S. and other patents and other intellectual property;
     
  our ability to retain key executive members;
     
  our ability to internally develop new inventions and intellectual property;
     
  interpretations of current laws and the passages of future laws; and
     
  acceptance of our business model by investors.

 

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2018 (filed on March 25, 2019) entitled “Risk Factors” as well as in our other public filings.

 

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

  

 3 

 

     

DARIOHEALTH CORP. AND ITS SUBSIDIARY

 

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

 

AS OF JUNE 30, 2019

 

UNAUDITED

 

INDEX 

 

  Page
   
Consolidated Balance Sheets F-2 - F-3
   
Consolidated Statements of Comprehensive Loss F-4
   
Statements of Changes in Stockholders' Equity F-5 - F-6
   
Consolidated Statements of Cash Flows F-7
   
Notes to Consolidated Financial Statements F-8 - F-15

  

 F-1 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

 

    June 30,     December 31,  
    2019     2018  
    Unaudited        
ASSETS                
                 
CURRENT ASSETS:                
Cash and cash equivalents   $ 7,986     $ 10,997  
Restricted bank deposits     186       180  
Trade Receivables     278       168  
Inventories     1,819       1,377  
Other accounts receivable and prepaid expenses     553       591  
                 
Total current assets     10,822       13,313  
                 
LEASE DEPOSITS     44       43  
                 
OPERATING LEASE RIGHT OF USE ASSET     749       -  
                 
PROPERTY AND EQUIPMENT, NET     711       733  
                 
Total assets   $ 12,326     $ 14,089  

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 F-2 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY

 

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands (except stock and stock data)

 

    June 30,     December 31,  
    2019     2018  
    Unaudited        
             
LIABILITIES AND STOCKHOLDERS' EQUITY                
                 
CURRENT LIABILITIES:                
Trade payables   $ 2,384     $ 2,574  
Deferred revenues     1,398       736  
Operating lease liability     277       -  
Other accounts payable and accrued expenses     1,664       1,854  
                 
Total current liabilities     5,723       5,164  
                 
OPERATING LEASE LIABILITY     509       -  
                 
STOCKHOLDERS' EQUITY                
Common Stock of $0.0001 par value –
Authorized: 160,000,000 shares at June 30, 2019 (unaudited) and December 31, 2018; Issued and Outstanding: 42,859,386 and 36,607,755 shares at June 30, 2019 (unaudited) and December 31, 2018, respectively
    8       8  
Preferred Stock of $0.0001 par value -
Authorized: 5,000,000 shares at June 30, 2019 (unaudited) and December 31, 2018; Issued and Outstanding: None at June 30, 2019 (unaudited) and December 31, 2018
    -       -  
Additional paid-in capital     106,098       98,171  
Accumulated deficit     (100,012 )     (89,254 )
                 
Total stockholders' equity     6,094       8,925  
                 
Total liabilities and stockholders' equity   $ 12,326     $ 14,089  

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 F-3 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S. dollars in thousands (except stock and stock data)

  

    Three months ended
June 30
    Six months ended
June 30
 
    2019     2018     2019     2018  
    Unaudited     Unaudited  
                         
Revenues   $ 1,651     $ 2,059     $ 3,893     $ 3,815  
Cost of revenues     1,325       1,537       3,009       2,741  
                                 
Gross profit     326       522       884       1,074  
                                 
Operating expenses:                                
Research and development   $ 991     $ 1,010     $ 1,993     $ 1,752  
Sales and marketing     2,993       2,369       6,939       4,233  
General and administrative     1,704       2,936       2,677       3,797  
                                 
Total operating expenses     5,688       6,315       11,609       9,782  
                                 
Operating loss     (5,362 )     (5,793 )     (10,725 )     (8,708 )
                                 
Financial expenses, net:                                
Revaluation of warrants     -       *)-       -       1  
Other financial expense, net     (20 )     (45 )     (33 )     (50 )
                                 
Total financial expenses, net     (20 )     (45 )     (33 )     (49 )
                                 
Net loss   $ (5,382 )   $ (5,838 )   $ (10,758 )   $ (8,757 )
                                 
Deemed dividend related to warrant exchange   $ -     $ 493     $ -     $ 493  
Net loss attributable to holders of Common Stock   $ (5,382 )   $ (6,331 )   $ (10,758 )   $ (9,250 )
                                 
Net loss per share                                
                                 
Basic and diluted loss per share   $ (0.13 )   $ (0.32 )   $ (0.27 )   $ (0.52 )
Weighted average number of Common Stock used in computing basic and diluted net loss per share     42,519,825       19,801,891       39,654,408       17,758,064  

  

The accompanying notes are an integral part of the consolidated financial statements.

 

 F-4 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY

 

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

U.S. dollars in thousands (except stock and stock data)

 

                Additional           Total  
    Common Stock     Preferred Stock     paid-in     Accumulated     stockholders’  
    Number     Amount     Number     Amount     capital     deficit     equity  
                                           
Balance as of December 31, 2018     36,607,775     $ 8       -     $ -     $ 98,171     $ (89,254 )   $ 8,925  
                                                         
Payment for executives and directors under Stock for Salary Program     213,398       *)-       -       -       210       -       210  
Stock-based compensation     -       -       -       -       106       -       106  
Net loss     -       -       -       -       -       (5,376 )     (5,376 )
                                                         
Balance as of March 31, 2019 (unaudited)     36,821,173     $ 8       -     $ -     $ 98,487     $ (94,630 )     3,865  
                                                         
Payment for executives under Stock for Salary Program     142,624       *)-       -       -       141       -       141  
Exercise of Options     8,104       *)-       -       -       *)-       -       -  
Public Offering     4,855,341                               6,558       -       6,558  
Issuance of Common Stock to directors and employees     1,032,144       *)-       -       -       795               795  
Stock-based compensation     -       -       -       -       117       -       117  
Net loss     -       -       -       -       -       (5,382 )     (5,382 )
                                                         
Balance as of June 30, 2019 (unaudited)     42,859,386     $ 8       -     $ -     $ 106,098     $ (100,012 )   $ 6,094  

 

*)       Represents an amount lower than $1.

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 F-5 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY

  

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

U.S. dollars in thousands (except stock and stock data)

 

                Additional           Total  
    Common Stock     Preferred Stock     paid-in     Accumulated     stockholders’  
    Number     Amount     Number     Amount     capital     deficit     equity  
                                           
Balance as of December 31, 2017     14,074,238     $ 7       -     $ -     $

74,892

    $ (70,958 )   $ 3,941  
                                                         
Payment for executives and directors under Stock for Salary Program     102,548       *)-       -       -       161       -       161  
Issuance of Common Stock to consultants and service provider     41,109       *)-       -       -       60       -       60  
Issuance of Common Stock, net of issuance cost     2,262,269       *)-       -       -       2,865       -       2,865  
Issuance of Preferred Stock, net of issuance cost     -       -       1,234,080       *)-       3,124       -       3,124  
Stock-based compensation     -       -       -       -       139       -       139  
Net loss     -       -       -       -       -       (2,919 )     (2,919 )
                                                         
Balance as of March 31, 2018 (unaudited)     16,480,164     $ 7       1,234,080     $ *)-     $ 81,241     $ (73,877 )     7,371  
                                                         
Payment for executives and directors under Stock for Salary Program     272,837        *)-       -       -       436       -       436  
Issuance of Common Stock to consultants and service provider     75,640        *)-       -       -       118       -       118  
Deemed dividend related to May 2018 warrant exchange     636,752                               493       (493 )     -  
Conversion of Preferred Stock to Common Stock     2,468,160               (1,234,080 )      *)-       -       -       -  
Issuance of Common Stock to directors and employees     1,147,840        *)-       -       -       1,779               1,779  
Stock-based compensation     -       -       -       -       289       -      

289

 
Net loss     -       -       -       -       -       (5,838 )    

(5,838

)
                                                         
Balance as of June 30, 2018 (unaudited)     21,081,393     $ 7       -     $ *)-     $ 84,356     $ (80,208 )   $ 4,155  

 

*)       Represents an amount lower than $1.

 

The accompanying notes are an integral part of the consolidated financial statements.

 

 F-6 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S. dollars in thousands

 

    Six months ended
June 30,
 
    2019     2018  
    Unaudited  
             
Cash flows from operating activities:                
Net loss   $ (10,758 )   $ (8,757 )
Adjustments required to reconcile net loss to net cash used in operating activities:                
Stock-based compensation and Common Stock to service providers     1,310       2,651  
Depreciation     93       101  
Amortization of operating lease right of use     130       -  
Increase is trade receivables     (110 )     (66 )
Decrease in accounts receivables and prepaid expenses     38       47  
Decrease (increase) in inventories     (442 )     16  
Increase (decrease) in trade payables     (190 )     226  
Increase (decrease) in other accounts payable and accrued expenses     (131 )     939  
Increase in deferred revenues     662       50  
Change in operating lease liability     (93)       -  
Change in fair value of warrants to purchase shares of Common Stock     -       (1 )
                 
Net cash used in operating activities     (9,491 )     (4,794 )
                 
Cash flows from investing activities:                
Maturities (investment) of restricted bank deposit     (6 )     76  
Investment in lease deposits     (1 )     -  
Purchase of property and equipment     (71 )     (23 )
                 
Net cash provided by (used in) investing activities     (78 )     53  
                 
Cash flows from financing activities:                
Proceeds from issuance of Common Stock, Preferred Stock and warrants, net of issuance cost     6,558       6,034  
                 
Net cash provided by financing activities     6,558       6,034  
                 
Increase (decrease) in cash and cash equivalents     (3,011 )     1,293  
Cash and cash equivalents at the beginning of the period     10,997       3,718  
                 
Cash and cash equivalents at the end of the period   $ 7,986     $ 5,011  
                 
Non-cash investing and financing activities:                
                 
Payment for directors and consultants under Shares for Salary Program   $ 59     $ 201  

  

The accompanying notes are an integral part of the consolidated financial statements. 

 

 F-7 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 1: - GENERAL

 

  a.

DarioHealth Corp. (formerly LabStyle Innovations Corp.) (the “Company”) was incorporated in Delaware and commenced operations on August 11, 2011.

 

Dario Health is a leading Global Digital Therapeutics (DTx) company revolutionizing the way people with chronic conditions manage their health. By delivering personalized evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching, DarioHealth has developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way.

 

DarioHealth’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutics interventions. Being one of the highest rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. DarioHealth is rapidly expanding its solutions for additional chronic conditions such as hypertension and moving into new geographic markets.

 

DarioHealth’s digital therapeutic platform has been designed with a ‘user-first’ strategy, focusing on the user’s needs first and foremost, and user experience and satisfaction. User satisfaction is constantly measured and drives, all company processes, including our technology design.

 

  b. The Company’s wholly owned subsidiary, LabStyle Innovation Ltd. (“Ltd.” or “Subsidiary”), was incorporated and commenced operations on September 14, 2011 in Israel. Its principal business activity is to hold the Company’s intellectual property and to perform research and development, manufacturing, marketing and other business activities.

 

  c. During the six months ended June 30, 2019, the Company incurred operating losses and negative cash flows from operating activities amounting to $10,725 and $9,491, respectively. The Company will be required to obtain additional liquidity resources in order to support the commercialization of its products and maintain its research and development activities. The Company is addressing its liquidity needs by seeking additional funding from public and/or private sources and by ramping up its commercial sales. There are no assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required for the short and long-term development and commercialization of its product.

 

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

 

  d.

On March 4, 2016, the Company's common stock (the “Common Stock”) and warrants were approved for listing on Nasdaq Capital Market under the symbols “DRIO” and “DRIOW,” respectively.

 

  NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES

 

  a.

The significant accounting policies applied in the audited annual consolidated financial statements of the Company as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 are applied consistently in these unaudited interim consolidated financial statements, except for the below:

 

Effective as of January 1, 2019, the Company adopted Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers” (ASC 606) and ASU No. 2016-02,  “Leases” (ASC 842). For further information refer to Note 2b.

 

 F-8 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
U.S. dollars in thousands (except stock and stock data)

 

  NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)

 

  b. Adoption of new accounting principles

 

In May 2014, the Financial Accounting Standards Board (the “FASB”) issued ASC 606. The standard replaced the revenue recognition guidance in U.S. generally accepted accounting principles under ASC 605, and was required to be applied retrospectively to each prior period presented, or applied using a modified retrospective method with the cumulative effect recognized in the beginning retained earnings during the period of initial application. Subsequently, the FASB issued several additional ASUs related to ASU No. 2014-09, collectively referred to as the “new revenue standards”, which became effective for the Company beginning January 1, 2019. The Company adopted the standard using the modified retrospective method. The adoption of ASC 606 did not have a significant impact on the Company’s Condensed Consolidated Financial Statements. See Note 5 for further information.

 

The Company recognizes revenue when (or as) it satisfies performance obligations by transferring promised products or services to its customers in an amount that reflects the consideration the Company expects to receive. The Company applies the following five steps: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied.

 

The Company considers customer and distributers purchase orders to be the contracts with a customer. For each contract, the Company considers the promise to transfer tangible products and services, each of which are distinct, to be the identified performance obligations. In determining the transaction price, the Company evaluates whether the price is subject to rebates and adjustments to determine the net consideration to which the Company expects to receive. As the Company’s standard payment terms are less than one year, the contracts have no significant financing component. The Company allocates the transaction price to each distinct performance obligation based on their relative standalone selling price. Revenue from tangible products is recognized when control of the product is transferred to the customer (i.e., when the Company’s performance obligation is satisfied), which typically occurs at shipment. The revenues from fixed-price services are recognized ratably over the contract period and the costs associated with these contracts are recognized as incurred. The Company's standard arrangements with its customers typically do not allow for rights of return.

  

In February 2016, the FASB issued ASU No. 2016-02, “Leases” (ASC 842). The standard requires lessees to recognize almost all leases on the balance sheet as a right-of-use (“ROU”) asset and a lease liability and requires leases to be classified as either an operating or a finance type lease. The standard excludes leases of intangible assets or inventory. The standard becomes effective for the Company beginning January 1, 2019. The Company adopted ASC 842 using the modified retrospective approach, by applying the new standard to all leases existing at the date of initial application. Results and disclosure requirements for reporting periods beginning after January 1, 2019 are presented under ASC 842, while prior period amounts have not been adjusted and continue to be reported in accordance with our historical accounting under ASC 840. The Company elected the package of practical expedients permitted under the standard, which also allowed the Company to carry forward historical lease classifications. The Company also elected the practical expedient related to treating lease and non-lease components as a single lease component for all equipment leases as well as electing a policy exclusion permitting leases with an original lease term of less than one year to be excluded from the ROU assets and lease liabilities.

 

 F-9 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES (Cont.)

 

As a result of the adoption of ASC 842 on January 1, 2019, the Company recorded both operating lease ROU assets and operating lease liabilities of $847. The adoption did not impact the Company's beginning retained earnings, or prior year condensed consolidated statements of comprehensive loss and statements of cash flows. See Note 7 for further information on leases.

 

Under ASU No. 2016-02, “Leases” (ASC 842), the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease assets and liabilities. These amounts include payments affected by the Consumer Price Index. As most of the Company's leases do not provide an implicit rate, the Company, with the assistance of a third party valuation firm, determined the incremental borrowing rate in determining the present value of lease payments. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. The Company lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.

 

Operating leases are included in operating lease ROU assets, current and non-current operating lease liabilities, on the Company's condensed consolidated balance sheets.

  

In June 2018, the FASB issued ASU 2018-07, “Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.” This ASU supersedes ASC 505-50, “Equity—Equity Based Payments to Non-Employees,” and expands the scope of ASC 718, “Compensation – Stock Compensation,” to include all share-based payment arrangements related to the acquisition of goods and services from both nonemployees and employees. The standard becomes effective for the Company beginning January 1, 2019. The adoption of this guidance did not have a material impact on the Company’s consolidated financial statements.

 

  c. Recently issued accounting pronouncements, not yet adopted:

 

In August 2018, the FASB issued ASU No. 2018-13, “Fair Value Measurement (Topic 820) - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement”, which is designed to improve the effectiveness of disclosures by removing, modifying and adding disclosures related to fair value measurements. ASU No. 2018-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years; the ASU allows for early adoption in any interim period after issuance of the update. The adoption of this ASU is not expected to have a significant impact on the Company’s consolidated financial statements.

 

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses” (Topic 326), to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of this ASU is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. ASU No. 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years; the ASU allows for early adoption as of the beginning of an interim or annual reporting period beginning after December 15, 2018. The Company is currently assessing the impact this ASU will have on its consolidated financial statements. 

 

  NOTE 3: - UNAUDITED INTERIM FINANCIAL STATEMENTS

 

The accompanying unaudited interim consolidated financial statements as of June 30, 2019, have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for a fair presentation of the Company's consolidated financial position as of June 30, 2019, and the Company's consolidated results of operations and the Company's consolidated cash flows for the three and six months ended June 30, 2019. Results for the three and six months ended June 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

 

 F-10 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 4: - INVENTORIES

 

    June 30,     December 31,  
    2019     2018  
    Unaudited        
             
Raw materials   $ 602     $ 424  
Finished products     1,217       953  
                 
    $ 1,819     $ 1,377  

 

During the six months’ period ended June 30, 2019, and the year ended December 31, 2018, total inventory write-off expenses amounted to $0 and $190, respectively.

 

  NOTE 5: - REVENUE

 

On January 1, 2019, the Company adopted ASC 606 using the modified retrospective method and applied the standard to those contracts which were not completed as of January 1, 2019. Results for reporting periods beginning after January 1, 2019 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with the historic accounting under ASC 605.

 

The following tables represent our total revenues for the three and six months ended June 30, 2019 and 2018 by product type (prior period amounts have not been adjusted under the modified retrospective method):

 

    Three months ended
June 30
    Six months ended
June 30
 
    2019     2018     2019     2018  
    Unaudited     Unaudited  
                         
Products   $ 1,235     $ 2,059     $ 3,071     $ 3,815  
Services     416       -       822       -  
                                 
      1,651       2,059       3,893       3,815  

 

The Company recognizes contract liabilities, or deferred revenues, when it receives advance payments from customers before performance obligations primarily related services have been performed. Advance payments are received at the beginning of the service period and the related deferred revenues are reclassified to revenue ratably over the service period. The balance of deferred revenues approximates the aggregate amount of the transaction price allocated to the unsatisfied performance obligations at the end of reporting period.

 

The following table presents the significant changes in the deferred revenue balance during the six months ended June 30, 2019:

 

Balance, beginning of the period   $ 736  
New performance obligations     2,011  
Reclassification to revenue as a result of satisfying performance obligations     (1,349 )
Balance, end of the period   $ 1,398  

 

Because all performance obligations in the Company’s contracts with customers relate to contracts with a duration of less than one year, the Company has elected to apply the optional exemption and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period.

 

 F-11 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 6: - COMMITMENTS AND CONTINGENT LIABILITIES

 

From time to time the Company is involved in claims and legal proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss.

 

  NOTE 7: - LEASES

 

At the beginning of fiscal 2019, the Company adopted ASC 842. The adoption of ASC 842 did not have a significant impact on the Company’s consolidated financial statements.

 

The Company has entered into various non-cancelable operating lease agreements for certain of its offices and car leases. The Company's leases have original lease periods expiring between 2019 and 2022. Many leases include one or more options to renew. The Company does not assume renewals in determination of the lease term unless the renewals are deemed to be reasonably assured at lease commencement. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

 

The components of lease costs, lease term and discount rate are as follows:

 

    Six Months Ended  
    June 30, 2019  
       
Lease cost        
    Operating lease cost   $ 133  
    Short term lease cost     19  
    Variable lease cost     37  
Total lease cost     189  
         
Weighted Average Remaining Lease Term        
Operating leases     3.23 years  
         
Weighted Average Discount Rate        
Operating leases     7.23 %

 

The following is a schedule, by years, of maturities of lease liabilities as of June 30, 2019:

 

    Operating Leases  
The remainder of 2019   $ 146  
2020     276  
2021     246  
2022     209  
Total undiscounted cash flows     877  
Less imputed interest     (91
Present value of lease liabilities   $ 786  

 

Supplemental cash flow information related to leases are as follows:

 

    Six Months Ended  
    June 30, 2019  
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flows from operating leases   $ 152  
Lease liabilities arising from obtaining right-of-use assets:        
Operating leases   $ 878  

 

 F-12 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 8: - STOCKHOLDERS' EQUITY

 

  a.

In January and April 2019, 356,022 shares of Common Stock were issued to certain members of the Board of Directors, officers and employees of the Company as consideration for a reduction in or waiver of cash salary, bonuses or fees owed to such individuals, totaling $351. The shares were issued under the Company’s Amended and Restated 2012 Equity Incentive Plan (the “2012 Plan”).

 

  b.

In April 2019, the Company’s Compensation Committee of the Board of Directors approved the grant of an aggregate of 1,032,144 shares to directors, officers, employees and consultants of the Company, and the grant of 584,698 options to employees and consultants of the Company, respectively, at exercise prices of $0.72 and $0.77 per share. The stock options vest over a period of three years commencing on the respective grant dates. All of the aforementioned options have a six-year terms. All options were issued under the 2012 Plan.

 

  c.

On May 24, 2019, the Company closed a public offering (the “2019 Public Offering”) of (i) 4,855,341 shares of Common Stock, at a price of $0.60 per share and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 7,175,525 shares of Common Stock, for aggregate consideration of $6,558, net of issuance expenses.

 

The Pre-Funded Warrants was sold at a public offering price of $0.5999 per Pre-Funded Warrant, which represents the per share public offering price per Share, less a $0.0001 per share exercise price for each such Pre-Funded Warrant. The shares and Pre-Funded Warrants were offered, issued and sold pursuant to a shelf registration statement filed with the Securities and Exchange Commission. The Pre-Funded Warrants have been accounted for as equity instruments.

 

The Pre-Funded Warrants are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with any group that the holder is a member, would beneficially own more than 4.99% (or, at the election of the purchaser, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. A holder of Pre-Funded Warrants may terminate, increase or decrease this percentage by providing at least 61 days’ prior notice to the Company. A holder of Pre-Funded Warrants is also subject to a limitation on exercise of the Pre-Funded Warrant if such exercise would result in such holder, together with any group that the holder is a member, beneficially owning more 19.99% of the number of shares of common stock outstanding immediately before giving effect to such exercise, unless shareholder approval is obtained.

 

 F-13 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 8: - STOCKHOLDERS' EQUITY (Cont.)

 

  d. Stock option compensation:

 

Transactions related to the grant of options to employees, directors and non-employees under the above plans during the six month period ended June 30, 2019, were as follows:

 

    Number of
options
    Weighted
average
exercise
price
    Weighted
average
remaining
contractual
life
    Aggregate
Intrinsic
value
 
          $     Years     $  
                         
Options outstanding at beginning of year     1,787,801       5.59       4.32       368  
Options granted     584,698       0.73                  
Options exercised     (8,104 )     0.00                  
Options expired     (61,182 )     4.36                  
Options forfeited     (55,588 )     1.58                  
                                 
Options outstanding at period end (unaudited)     2,247,625       4.47       4.33       217  
                                 
Options vested and expected to vest at period end (unaudited)     2,015,682       4.58       4.30       216  
                                 
Exercisable at period end (unaudited)     1,309,145       6.88       3.55       348  

 

The aggregate intrinsic value in the table above represents the total intrinsic value (the difference between the Company's closing stock price on the last day of the second quarter of 2019 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on June 30, 2019. This amount is impacted by the changes in the fair market value of the Common Stock.

 

As of June 30, 2019, the total amount of unrecognized stock-based compensation expense was approximately $561 which will be recognized over a weighted average period of 1.29 year.

 

The following table presents the assumptions used to estimate the fair values of the options granted to employees, directors and non-employees in the period presented:

 

    Three months ended
June 30,
 
    2019     2018  
             
Volatility     85.53%-90.82 %     85.99%-105.38 %
Risk-free interest rate     2.26%-2.28 %     2.66%-2.77 %
Dividend yield     0 %     0 %
Expected life (years)      3.5-4.5         3.5-5.94  

  

The total compensation cost related to all of the Company's equity-based awards recognized during the six month period ended June 30, 2019, and 2018 was comprised as follows:

 

    Six months ended
June 30,
 
    2019     2018  
    Unaudited  
Cost of revenues   $ 57     $ 83  
Research and development     111       299  
Sales and marketing     95       280  
General and administrative     1,047       1,989  
Total stock-based compensation expenses   $ 1,310     $ 2,651  

 

 F-14 

 

 

DARIOHEALTH CORP. AND ITS SUBSIDIARY
 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands (except stock and stock data)

 

  NOTE 9: - FINANCIAL EXPENSES, NET

 

    Six months ended
June 30,
 
    2019     2018  
    Unaudited  
             
Bank charges   $ 14     $ 7  
Foreign currency translation adjustments     19       42  
                 
Total financial expenses, net   $ 33     $ 49  

 

  NOTE 10: - SUBSEQUENT EVENTS

 

  a. In July 2019, 741,894 shares of Common Stock were issued to certain members of the Board of Directors, officers and employees of the Company as consideration for a reduction in or waiver of cash salary, fees and bonuses owed to such individuals, totaling $445. The shares were issued under the 2012 Plan.

 

 F-15 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Readers are advised to review the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and related notes thereto in our Annual Report on Form 10-K for the year ended December 31, 2018. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” You should review the “Risk Factors” section of our Annual Report for the fiscal year ended December 31, 2018 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

The following financial data in this narrative are expressed in thousands, except for stock and stock data or as otherwise noted.

 

We are a leading Global Digital Therapeutics (DTx) company revolutionizing the way people manage their health across the chronic condition spectrum by delivering evidence-based interventions that are driven by precision data analytics, high quality software, and personalized coaching. We have developed a novel approach that empowers individuals to adjust their lifestyle in a unique and holistic way. Our cross-functional team operates at the intersection of life science, behavioral science, and software technology to deliver seamlessly integrated and highly engaging therapeutic interventions. Already one of the highest-rated diabetes solutions, its user-centric approach is loved by tens of thousands of customers around the globe. We are rapidly expanding solutions for additional chronic conditions such as hypertension, using a performance-based approach to improve the health of users managing chronic disease.

 

Our flagship product, Dario, which we also refer to as our Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on an innovative, multi-feature software application to track and monitor all facets of diabetes, combined with a stylish, ‘all-in-one’, pocket-sized, blood glucose monitoring device, which we call the Dario Blood Glucose Monitoring System, that essentially turns a smartphone into a glucometer. In addition, our product offerings will focus on the newly launched Dario Engage software platform, where we digitally engage with Dario users, assist them in monitoring their chronic illnesses and provide them with coaching, support, digital communications and real time alerts, trends and pattern analysis. The Dario Engage platform can be leveraged by our potential partners, such as clinics, health care service providers, employers and payers for scalable monitoring of people with diabetes in a cost-effective manner, which we expect will open for us additional revenue streams. Finally, we intend to utilize the data we obtain from our Dario Smart Diabetes Management Solution and Dario Engage platform to develop our upcoming healthcare analytics program, Dario Intelligence. As such our solutions will span the full spectrum of disease monitoring, user-centric engagement, coaching tools, and big data and intelligence solutions. We have obtained regulatory clearance or approval for the Dario Blood Glucose Monitoring System in the U.S., Canada, the E.U., Israel and Australia, among others. We believe that our targeted health platform is a highly personalized preventative and proactive approach to health improvement based on individual behavior and treatment, tailored to each person’s unique profile.

 

Our principal operating subsidiary, LabStyle Innovation Ltd., is an Israeli company with its headquarters in Caesarea, Israel. We were formed on August 11, 2011 as a Delaware corporation with the name LabStyle Innovations Corp. On July 28, 2016, we changed our name to DarioHealth Corp.

 

We commenced a commercial launch of our free application in the United Kingdom in late 2013 and commenced an initial soft launch of the full Dario solution (including the app and the Dario Blood Glucose Monitoring System) in selected jurisdictions in March 2014. We continued to scale up launch during 2014 in the United Kingdom, the Netherlands and New Zealand, and during 2015 in Australia, Israel and Canada, with the goal of collecting customer feedback to refine our longer-term roll-out strategy. We are consistently adding new additional features and functionality in making Dario the new standard of care in diabetes data management.

 

Through our Israeli subsidiary, Labstyle Innovation Ltd., our plan of operations is to continue the development of our software and hardware offerings and related technology. During 2015, we successfully launched the Dario Smart Diabetes Management Solution according to plan and are currently expanding the launch to other jurisdictions. In 2016, we established our direct to consumer model in the U.S. to achieve higher and faster penetration into the market during the launch phase. We have invested in a robust digital marketing department with in-house platforms, experienced personnel and robust infrastructures to support expected growth of users and online subscribers in this market. During the third quarter of 2016 we expanded these efforts to include Australia as well. In 2017, we expanded our direct to consumer marketing efforts in the United Kingdom in cooperation with our local distributor and launched similar marketing efforts in Germany. In support of these goals, we intend to utilize our funds for the following activities:

 

  · ramp up of mass production, marketing and distribution and sales efforts related to the Dario Smart Diabetes Management Solution and the DarioEngage platform;

 

 4 

 

  

  · develop our customer support and telemarketing services in order to support the expect growth of our revenues and the increase of user, and service provider who will use our platform to better serve people with diabetes and improve their clinical outcome;

 

  · continued product and software development, and related activities (including costs associated with application development and data storage capabilities as well as any necessary design modifications to the various elements of the Dario Smart Diabetes Management Solution, the DarioEngage platform and the Dario Intelligence tools and capabilities);

 

  · continued work on registration of our patents worldwide;

 

  · regulatory and quality assurance matters;

 

  · professional fees associated with being a publicly reporting company; and

 

  · general and administrative matters.

 

Readers are cautioned that, according to our management’s estimates, based on our budget and the initial launch of our commercial sales, we believe that we will have sufficient resources to continue our activity into January 2020 without raising additional capital. This includes an amount of anticipated inflows from sales of Dario through direct sales in the United States and through distribution partners. As such, we have a significant present need for capital. If we are unable to scale up our commercial launch of Dario or meet our commercial sales targets (or if we are unable to ramp up revenues), and if we are unable to obtain additional capital resources in the near term, we may be unable to continue activities, absent a material alterations in our business plans and our business might fail.

 

Critical Accounting Policies

 

Please see Note 2 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. In addition, reference is made to Part I, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operation of our Annual Report on Form 10-K for the year ended December 31, 2018 (filed on March 25, 2019) with respect to our Critical Accounting Policies. There have been no other material changes to our critical accounting policies and estimates since our Annual Report on Form 10-K for the year ended December 31, 2018. 

 

Results of Operations

 

Comparison of the six months ended June 30, 2019 and 2018 (dollar amounts in thousands)

 

Revenues

 

Revenues for the three and six months ended June 30, 2019, amounted to $1,651 and $3,893, respectively, compared to revenues of $2,059 and $3,815 during the three and six months ended June 30, 2018, representing a decrease of 20% and an increase of 2%, respectively. The decrease in revenues for the three months ended June 30, 2019, compared to the three months ended June 30, 2018, is due to a decrease in our direct to consumer (“D2C”) acquisition in the second quarter of 2019, and an increase in our provision for deferred income. The decision to decrease D2C acquisition is a result of our efforts to shift resources from direct to consumer sales to sales through business to business channels that are with lower cost per acquisition. The increase in revenues for the six months ended June 30, 2019, compared to the six months ended June 30, 2018, is mainly as a result of higher revenues in the first quarter of 2019 compared to the first quarter of 2018.

 

Revenues were derived mainly from the sales of Dario’s components, including the Dario Blood Glucose Monitoring System itself and the membership offering, through direct sales to consumers located mainly in the United States and Australia, through our on-line store and distributors.

 

Cost of Revenues

 

During the three and six months ended June 30, 2019, we recorded costs related to revenues in the amount of $1,325 and $3,009 respectively, compared to recorded costs related to revenues of $1,537 and $2,741 during the three and six months ended June 30, 2018, representing a decrease of 14% and an increase of 10%, respectively. The decrease in costs related to revenues in the three months ended June 30, 2019, compared to three months ended June 30, 2018, is mainly a result of a decrease in the sales of our products during that period. The increase in costs related to revenues in the six months ended June 30, 2019, compared to the six months ended June 30, 2018, is mainly as a result of an increase in the sales of our products during the first quarter of 2019.

 

 5 

 

  

Cost of revenues consist mainly of cost of device production, employees' salaries and related overhead costs, depreciation of production line and related cost of equipment used in production, shipping and handling costs and inventory write-downs.

 

Gross Profit

 

Gross profit for the three and six months ended June 30, 2019, amounted to $326 (19.7% of revenues) and $884 (22.7% of revenues), respectively, compared to $522 (25.4% of revenues) and $1,074 (28.2% of revenues) during the three and six months ended June 30, 2018. The decrease in gross profit for the three and six months ended June 30, 2019, compared to the three and six months ended June 30, 2018, is mainly as a result of the decrease in product sales in the second quarter and the deferral of a portion of the revenues generated from our membership offering.

 

Research and Development Expenses

 

Our research and development expenses decreased by $19, or 2%, to $991 for the three months ended June 30, 2019, compared to $1,010 for the three months ended June 30, 2018, and increased by $241, or 14%, to $1,993 for the six months ended June 30, 2019 compared to $1,752 for the six months ended June 30, 2018. The second quarter decrease for the three months ended June 30, 2019, compared to the three months ended June 30, 2018, was mainly due to decreases in stock-based compensation, mostly offset by an increase in payroll and other research and development costs relating primarily to product development. The second quarter increase for the six months ended June 30, 2019, compared to the six months ended June 30, 2018, was mainly due to increases in payroll and other research and development costs relating primarily to product development.

 

Research and development expenses consist mainly of payroll expenses to employees involved in research and development activities, expenses related to our Dario software application and related Dario Blood Glucose Monitoring System device, labor contractors and engineering expenses, depreciation and maintenance fees related to equipment and software tools used in research and development, clinical trials performed in the United States to satisfy the FDA product approval requirements and facilities expenses associated with and allocated to research and development activities.

  

Sales and Marketing Expenses

 

Our sales and marketing expenses increased by $624, or 26%, to $2,993 for the three months ended June 30, 2019, compared to $2,369 for the three months ended June 30, 2018, and increased by $2,706, or 64%, to $6,939 for the six months ended June 30, 2019, compared to $4,233 for the six months ended June 30, 2018. These increases were mainly due to expanding our sales and marketing activities in the United States, increases in costs of online marketing campaigns, and the costs associated with employee payroll.

 

Sales and marketing expenses consist mainly of payroll expenses, online marketing campaigns of the Dario, trade show expenses, customer support expenses and marketing consultants and subcontractors.

 

General and Administrative Expenses

 

Our general and administrative expenses decreased by $1,232, or 42%, to $1,704 for the three months ended June 30, 2019, compared to $2,936 for the three months ended June 30, 2018, and decreased by $1,120, or 29%, to $2,677 for the six months ended June 30, 2019, compared to $3,797 for the six months ended June 30, 2018. These decreases were mainly due to decreases in share-based compensation.

 

Our general and administrative expenses consist mainly of payroll and stock-based compensation expenses for management, employees, directors and consultants, legal fees, patent registration, expenses related to investor relations, as well as our office rent and related expenses.

 

Financial Expenses, net

 

Our financial expenses for the three months ended June 30, 2019, were $20, representing a decrease of 56%, compared to finance expenses of $45 for the three months ended June 30, 2018. Our financial expenses for the six months ended June 30, 2019, were $33, representing a decrease of 33%, compared to finance expenses $49 for the six months ended June 30, 2018. The decreases in financial expenses for the three months ended June 30, 2019, as compared to the three months ended June 30, 2018, and for the six months ended June 30, 2019, as compared to the six months ended June 30, 2018, are mainly attributable to differences in foreign currency translation expenses.

 

 6 

 

 

Financial expenses include mainly bank charges, lease liability translation differences and foreign currency translation differences.

 

Net loss

 

Net loss decreased by $456, or 8%, to $5,382 for the three months ended June 30, 2019, compared to a net loss of $5,838 for the three months ended June 30, 2018, and increased by $2,001, or 22.9%, to $10,758 for the six months ended June 30, 2019, compared to $8,757 for the six months ended June 30, 2018.

   

The decrease in net loss for the three months ended June 30, 2019, compared to the three months ended June 30, 2018, was mainly due to a decrease in our operating expenses recorded in the three months ended June 30, 2019, compared to the three months ended June 30, 2018. The increase in net loss for the six months ended June 30, 2019, compared to the six months ended June 30, 2018, was mainly due to the increase in operating expenses recorded in the six months ended June 30, 2019, compared to the six months ended June 30, 2018.

  

Non-GAAP Financial Measures

 

The factors described above resulted in net loss attributable to common stockholders of $10,758 and $8,757 for the six months ended June 30, 2019, and 2018, respectively.

 

To supplement our unaudited condensed consolidated financial statements presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) within this Quarterly Report on Form 10-Q, management provides certain non-GAAP financial measures (“NGFM”) of the Company’s financial results, including such amounts captioned: “net loss before interest, taxes, depreciation, and amortization” or “EBITDA”, and “Non-GAAP Adjusted Loss”, as presented herein below. Importantly, we note the NGFM measures captioned “EBITDA” and “Non-GAAP Adjusted Loss” are not recognized terms under U.S. GAAP, and as such, they are not a substitute for, considered superior to, considered separately from, nor as an alternative to, U.S. GAAP and /or the most directly comparable U.S. GAAP financial measures.

 

Such NGFM are presented with the intent of providing greater transparency of information used by us in our financial performance analysis and operational decision-making. Additionally, we believe these NGFM provide meaningful information to assist investors, shareholders, and other readers of our unaudited condensed consolidated financial statements, in making comparisons to our historical financial results, and analyzing the underlying financial results of our operations. The NGFM are provided to enhance readers’ overall understanding of our current financial results and to provide further information to enhance the comparability of results between the current year period and the prior year period.

 

We believe the NGFM provide useful information by isolating certain expenses, gains, and losses, which are not necessarily indicative of our operating financial results and business outlook. In this regard, the presentation of the NGFM herein below, is to help the reader of our unaudited condensed consolidated financial statements to understand the effects of the non-cash impact on our (U.S. GAAP) unaudited condensed consolidated statement of operations of the revaluation of the warrants and the expense related to stock-based compensation, each as discussed herein above.

 

A reconciliation to the most directly comparable U.S. GAAP measure to NGFM, as discussed above, is as follows:

 

    Three Months Ended June 30,
(in thousands)
 
    2019     2018     $ Change  
                   
Net Loss Reconciliation                        
Net loss attributable to common stockholders – as reported   $ (5,382 )   $ (6,331 )   $ 949  
                         

Deemed dividend – related to warrant exchange

            493       (493 )
                         
Net Loss as reported     (5,382 )     (5,838 )     456  
                         
Adjustments                        
Depreciation expense     47       48       (1 )
Other financial expenses, net     20       45       (25 )
                         
EBITDA     (5,315 )     (5,745 )     430  
                         
Stock-based compensation expenses     1,053       2,421       (1,368 )
Revaluation of warrants     -        (* -        (* -  
                         
Non-GAAP adjusted loss   $ (4,262 )   $ (3,324 )   $ (938 )

 

 7 

 

  

    Six Months Ended June 30,
(in thousands)
 
    2019     2018     $ Change  
                   
Net Loss Reconciliation                        
Net loss attributable to common stockholders – as reported   $ (10,758 )   $ (9,250 )   $ (1,508 )
                         

Deemed dividend – related to warrant exchange

            493       (493 )
                         
Net Loss as reported     (10,758 )     (8,757 )     (2,001 )
                         
Adjustments                        
Depreciation expense     93       101       (8 )
Other financial expenses, net     33       50       (17 )
                         
EBITDA     (10.632 )     (8,606 )     (2,026 )
                         
Stock-based compensation expenses     1,310       2,651       (1,341 )
Revaluation of warrants             (1 )     1  
                         
Non-GAAP adjusted loss   $ (9,322 )   $ (5,956 )   $ (3,366 )

 

Liquidity and Capital Resources (amounts in thousands except for share and share amounts)

 

As of June 30, 2019, we had approximately $7,986 in cash and cash equivalents compared to $10,997 at December 31, 2018.

 

We have experienced cumulative losses of $100,012 from inception (August 11, 2011) through June 30, 2019, and have a stockholders’ equity of $6,094 at June 30, 2019. In addition, we have not completed our efforts to establish a stable recurring source of revenues sufficient to cover our operating costs and expect to continue to generate losses for the foreseeable future. There are no assurances that we will be able to obtain an adequate level of financing needed for our near term requirements or the long-term development and commercialization of our product. These conditions raise substantial doubt about our ability to continue as a “going concern.”

 

Since inception, we have financed our operations primarily through private placements and public offerings of our common stock and warrants to purchase shares of our common stock, receiving aggregate net proceeds totaling $77,737 as of June 30, 2019.

 

On May 24, 2019, the Company closed on its a firm commitment, underwritten public offering consisting of 4,855,341 shares of common stock and pre-funded warrants to purchase 7,175,525 shares of its common stock, pursuant to an underwriting agreement entered into with Craig-Hallum Capital Group LLC, as representative of the underwriters. The shares of common stock were sold at a public offering price of $0.60 per share and the pre-funded warrants were sold at a public offering price of $0.5999, for aggregate gross proceeds of approximately $6,558.

 

On February 28, 2018 and March 6, 2018, we closed two concurrent private placements offerings consisting of 2,262,269 shares of our common stock at $1.40 per share, 1,234,080 shares of our Series C Convertible Preferred Stock at $2.80 per share and warrants to purchase up to 3,784,351 shares of common stock for aggregate gross proceeds of approximately $6,623.

 

On September 13, 2018 and September 26, 2018, we closed two concurrent private placements offerings consisting of 4,266,800 shares of our common stock at $0.90 per share, 1,890,257 shares of our Series D Convertible Preferred Stock at $3.60 per share, and warrants to purchase up to 9,462,272 shares of common stock at an exercise price of $1.25 per share, for aggregate gross proceeds of approximately $10,645.

 

 8 

 

  

On December 13, 2018 and December 27, 2018, we closed a private placement offering of 3,050,000 shares of our common stock at a purchase price of $1.00 per share and warrants to purchase up to 3,050,000 shares of our common stock at an exercise price of $1.25 per share, for aggregate gross proceeds of approximately $3,050.

 

According to our management’s estimates, based on our budget and our commercial sales, we believe that we will have sufficient resources to continue our activity into April 2020 without raising additional capital. This includes an amount of anticipated inflows from sales of Dario through distribution partners and to direct customers.

  

As such, we have a significant present need for capital. If we are unable to scale up our commercial launch of Dario or meet our commercial sales targets (or if we are unable to generate any revenue at all), and if we are unable to obtain additional capital resources in the near term, we may be unable to continue activities absent material alterations in our business plans and our business might fail.

 

Additionally, readers are advised that available resources may be consumed more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. Should this occur, we will need to seek additional capital earlier than anticipated in order to fund (1) further development and, if needed, testing of our Dario Smart Diabetes Management Solution, (2) our efforts to obtain regulatory clearances or approvals necessary to be able to commercially launch Dario, DarioEngage and Dario Intelligence, (3) expenses which will be required in order to expand production of Dario, (4) sales and marketing efforts and (5) general working capital. Such funding may be unavailable to us on acceptable terms, or at all. Our failure to obtain such funding when needed could create a negative impact on our stock price or could potentially lead to the failure of our company. This would particularly be the case if we are unable to commercially launch Dario, DarioEngage and Dario Intelligence in the jurisdictions and in the timeframes we expect.

 

Cash Flows (dollar amounts in thousands)

 

The following table sets forth selected cash flow information for the periods indicated:

 

    June 30,  
    2019     2018  
    $     $  
Cash used in operating activities:     (9,491 )     (4,794 )
Cash provided by (used in) investing activities:     (78 )     53  
Cash provided by financing activities:     6,558       6,034  
      (3,011 )     1,293  

 

Net cash used in operating activities

 

Net cash used in operating activities was $9,491 for the six months ended June 30, 2019, an increase of 98% compared to $4,794 used in operations for the same period in 2018. Cash used in operations increased due to the increase in our operating loss, and a decrease in trade payables, other accounts payables and accrued expenses.

 

Net cash used in investing activities

 

Net cash used for investing activities was $78 for the six months ended June 30, 2019, an increase of 247% compared to cash derived from investing activities of $53 for the same period in 2018. Cash used for investing activities increased mainly due to investments in property and equipment and investments in restricted cash.

 

Net cash provided by financing activities

 

Net cash provided by financing activities was $6,558 for the six months ended June 30, 2019, an increase of 9% compared to $6,034 for the same period in 2018. This increase was due to a higher amount of funds raised from the sale of our equity securities.

 

Off-Balance Sheet Arrangements

 

As of June 30, 2019, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

We are a smaller reporting company and therefore are not required to provide the information for this item of Form 10-Q.

 

 9 

 

  

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this Report, our Chief Executive Officer and Chief Financial Officer, or the Certifying Officers, conducted evaluations of our disclosure controls and procedures. As defined under Sections 13a–15(e) and 15d–15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the term “disclosure controls and procedures” means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including the Certifying Officers, to allow timely decisions regarding required disclosures.

 

Based on their evaluation, the Certifying Officers concluded that, as of June 30, 2019, our disclosure controls and procedures were designed at a reasonable assurance level and were therefore effective.  

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2019, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on the Effectiveness of Internal Controls

 

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

 

 10 

 

  

PART II- OTHER INFORMATION

  

Item 6. Exhibits.

 

No.   Description of Exhibit
     
4.1   Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 22, 2019).
31.1*   Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
31.2*   Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a).
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350.
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350.
101.1*   The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, formatted in XBRL: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Statements of Changes in Stockholders’ Deficiency, (iv) Consolidated Statements of Cash Flows and (v) the Notes to Consolidated Financial Statements, tagged as blocks of text and in detail.

 

* Filed herewith.

 

** Furnished herewith.

 

 11 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  August 12, 2019   DarioHealth Corp.
       
  By:   /s/ Erez Raphael
    Name:   Erez Raphael
    Title: Chief Executive Officer
      (Principal Executive Officer)
       
   By:   /s/ Zvi Ben David
    Name: Zvi Ben David
    Title: Chief Financial Officer, Secretary and Treasurer (Principal Financial Officer)

 

 12